Share This Page
Drug Price Trends for NDC 28595-0804
✉ Email this page to a colleague
Average Pharmacy Cost for 28595-0804
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| HISTEX-DM SYRUP | 28595-0804-16 | 0.07148 | ML | 2025-12-17 |
| HISTEX-DM SYRUP | 28595-0804-16 | 0.07136 | ML | 2025-11-19 |
| HISTEX-DM SYRUP | 28595-0804-16 | 0.07131 | ML | 2025-10-22 |
| HISTEX-DM SYRUP | 28595-0804-16 | 0.07123 | ML | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 28595-0804
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 28595-0804
Introduction
NDC 28595-0804 pertains to a specific pharmaceutical product, part of the United States' National Drug Code (NDC) system, which provides precise identification of drug products. Analyzing its market landscape and developing reliable price projections requires comprehensive insights into manufacturing, demand, competitive landscape, regulatory environment, and healthcare utilization patterns. This report offers an in-depth examination tailored for stakeholders across the pharmaceutical supply chain, healthcare providers, and investors seeking actionable intelligence on this product’s market potential.
Product Overview
While specific product details for NDC 28595-0804 are not publicly detailed here, NDCs within the 28595 series typically relate to medications supplied through specific distribution channels—potentially injectable, specialty, or branded therapies. These products often address niche indications such as oncology, rare diseases, or chronic conditions. The precise therapeutic class and formulation significantly influence market dynamics, cost structures, and pricing strategies.
Current Market Landscape
Regulatory Status and Approvals
The regulatory environment shapes market access and pricing. If NDC 28595-0804 is FDA-approved, its approval pathway influences competitive barriers. A recent FDA approval accelerates market penetration, whereas an existing marketing authorization coupled with orphan or breakthrough status can command premium prices.
Manufacturers and Competitive Environment
The number of competitors manufacturing similar formulations critically affects pricing. Limited competition, especially in orphan diseases or specialized therapeutics, enables premium pricing. Conversely, a crowded market drives downward pressure on prices.
Key competitors within similar therapeutic categories include large pharmaceutical firms with established distribution channels, which can influence market share and pricing flexibility.
Indications and Patient Demographics
The target indications dictate demand size and patient demographics. Niche treatments in rare diseases may command higher prices due to limited patient populations, while broader indications may foster higher sales volumes but with price constraints.
Reimbursement and Pricing Trends
Reimbursement policies, payer negotiations, and formulary placements significantly impact pricing. Managed care trends increasingly tie drug reimbursement to clinical value, necessitating compelling evidence of efficacy and cost-effectiveness.
Market Trends
Supply Chain Dynamics
The ongoing impact of global supply chain disruptions, notably during the COVID-19 pandemic, has heightened awareness of production stability and inventory management. Suppliers with secure manufacturing hubs or diversified supply chains hold competitive advantages.
Pricing Trends in Specialty Drugs
The specialty drug sector, encompassing many high-cost injectables and biologics, has witnessed continued price escalation attributed to R&D investment recoveries, technological complexity, and personalized medicine approaches. However, payer pushback and external cost-control initiatives increasingly temper this trend.
Regulatory and Policy Influences
Recent legislations, such as the Inflation Reduction Act, aim to reign in drug prices, impacting future price trajectories, especially for high-cost specialty therapies.
Price Projections
Due to limited specific data on NDC 28595-0804, projections must consider analogous products in similar categories, historical pricing trends, and evolving regulatory influences.
| Time Frame | Price Trend Assumption | Projected Range | Rationale |
|---|---|---|---|
| Short-term (1-2 years) | Stabilization with minor fluctuations | $XX,XXX - $XX,XXX per unit | Reflects recent approval status and initial market acceptance. |
| Medium-term (3-5 years) | Moderate increase, aligned with inflation and value-based pricing | $XX,XXX - $XX,XXX per unit | Incorporates inflation, payer negotiations, and potential label expansions. |
| Long-term (5+ years) | Potential plateau or slight decrease due to biosimilar or generic competition | $XX,XXX or lower | Anticipated market entry of competitors or generic formulations. |
Note: Exact values are placeholders pending proprietary market-specific data.
Factors Influencing Future Price Trajectory
- Market Penetration and Adoption: Early uptake influenced by healthcare provider acceptance and formulary inclusion.
- Regulatory Changes: Approval of biosimilars or generics can depress prices.
- Therapeutic Advances: New delivery methods or indications can impact value perceptions.
- Payer Strategies: Value-based contract implementations and indication-specific pricing could modify price points.
- Manufacturing Costs: Innovations reducing cost base might enable sustained or reduced patient prices, balancing profitability.
Implications for Stakeholders
- Manufacturers: Strategic pricing must balance recovery of R&D investments, competitive position, and payer expectations.
- Healthcare Providers: Understanding pricing trends aids formulary and clinical decisions.
- Investors: Anticipating price trajectories influences valuation and investment strategies.
- Policy Makers: Monitoring potential price pressures informs reimbursement and regulation frameworks.
Key Takeaways
- The market for NDC 28595-0804 is influenced by the therapeutic category, competitive landscape, and regulatory context.
- Limited competition in rare or specialized therapies supports potential premium pricing in the short term.
- Price projections indicate moderate growth aligned with healthcare inflation and value-oriented pricing, with long-term stabilization or decline possible due to biosimilar entry.
- Strategic considerations such as patent life, indication expansion, and manufacturing efficiencies are critical for optimizing market position.
- Ongoing policy trends aim to temper fast-rising drug prices, potentially impacting future profitability.
FAQs
1. How does the regulatory environment impact pricing for NDC 28595-0804?
Regulatory approvals, especially expedited pathways or orphan designation, can support higher prices by creating market exclusivity and reducing competitive pressures.
2. What role do biosimilars or generics play in future price projections?
The entry of biosimilars or generics typically exerts downward pressure on prices, leading to potential price erosion over time, especially if patent protections lapse.
3. How does reimbursement policy influence the market for this drug?
Reimbursements governed by payers and pay-for-performance models can restrict prices or incentivize value-based pricing arrangements, directly impacting profitability.
4. What factors could lead to an increase in the drug's price over time?
Advancements in formulation, expanded indications, or increased demand due to clinical success can justify higher pricing, alongside inflation and supply chain stability.
5. How should manufacturers prepare for evolving market pressures?
Investing in clinical value demonstration, diversifying indications, optimizing manufacturing, and engaging with payers preemptively mitigate adverse pricing impacts.
References
- U.S. Food and Drug Administration (FDA). Drug Approvals and Regulatory Guidance.
- IQVIA. (2022). The Global Use of Medicine in 2022.
- Centers for Medicare & Medicaid Services (CMS). (2023). Drug Pricing and Reimbursement Policies.
- EvaluatePharma. (2022). Market Forecast and Trends in Specialty Pharmaceuticals.
- Congressional Research Service. (2021). Impacts of Biosimilar Competition on Drug Prices.
Note: Due to proprietary constraints, specific pricing figures remain illustrative. Continuous monitoring of regulatory updates, market developments, and competitive entries is essential for refined forecasts.
More… ↓
